NasdaqGS - Nasdaq Real Time Price USD

The Cooper Companies, Inc. (COO)

90.42 +0.01 (+0.01%)
At close: April 19 at 4:00 PM EDT
89.87 -0.55 (-0.61%)
After hours: April 19 at 5:55 PM EDT
Loading Chart for COO
DELL
  • Previous Close 90.41
  • Open 90.92
  • Bid 90.40 x 100
  • Ask 90.46 x 200
  • Day's Range 90.28 - 90.99
  • 52 Week Range 75.93 - 104.07
  • Volume 1,173,819
  • Avg. Volume 1,128,811
  • Market Cap (intraday) 17.972B
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) 61.93
  • EPS (TTM) 1.46
  • Earnings Date May 30, 2024
  • Forward Dividend & Yield 0.02 (0.02%)
  • Ex-Dividend Date Jul 26, 2023
  • 1y Target Est 108.36

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

www.coopercos.com

15,000

Full Time Employees

October 31

Fiscal Year Ends

Recent News: COO

Performance Overview: COO

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

COO
4.43%
S&P 500
4.14%

1-Year Return

COO
4.32%
S&P 500
19.55%

3-Year Return

COO
9.43%
S&P 500
18.68%

5-Year Return

COO
28.71%
S&P 500
70.99%

Compare To: COO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: COO

Valuation Measures

As of 4/19/2024
  • Market Cap

    17.97B

  • Enterprise Value

    20.61B

  • Trailing P/E

    62.03

  • Forward P/E

    25.71

  • PEG Ratio (5yr expected)

    11.17

  • Price/Sales (ttm)

    4.92

  • Price/Book (mrq)

    2.34

  • Enterprise Value/Revenue

    5.62

  • Enterprise Value/EBITDA

    23.03

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.93%

  • Return on Assets (ttm)

    2.69%

  • Return on Equity (ttm)

    3.87%

  • Revenue (ttm)

    3.67B

  • Net Income Avi to Common (ttm)

    290.8M

  • Diluted EPS (ttm)

    1.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    135.2M

  • Total Debt/Equity (mrq)

    39.68%

  • Levered Free Cash Flow (ttm)

    137.98M

Research Analysis: COO

Analyst Price Targets

95.00
108.36 Average
90.42 Current
125.00 High
 

Fair Value

Overvalued
% Return
90.42 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Research Reports: COO

  • COO: Lowering target price to $95.00

    COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $95.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     
  • Analyst Report: The Cooper Companies, Inc.

    The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

    Rating
    Neutral
    Price Target
     
  • COO: Raising target price to $104.00

    COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $104.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     
  • COO: Lowering target price to $103.00

    COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $103.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     

People Also Watch